FDC Roha facility successfully concludes USFDA audit
Mumbai: FDC has announced that the US Food and Drug Administration (USFDA) has successfully concluded the audit with no observations (Zero 483’s) at the company's Maharashtra manufacturing unit.
The inspection was conducted from 20th March 2023 to 24th March 2023.
Read also: Akums gets CDSCO panel nod to manufacture, market FDC Alfuzosin HCL, Tadalafil film coated tablets
Founded in 1936, FDC Limited is the pharmaceutical company headquartered in India. This facility is dedicated for Bulk APIs manufacturing. The Plant received the US-FDA approval 9 times in a row, since 1985. 90% of the APIs, manufactured at the Roha facility, are being exported to the USA, Canada, Japan, Malaysia, Europe and the Middle East countries
Read also: Morepen Labs Baddi facility clears USFDA inspection without any adverse observation
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd